Orkambi

Ivacaftor,

Lumacaftor

6.2 Moderate risk

Orkambi & Infective pulmonary exacerbation of cystic fibrosis

14.4%

of users reported Infective pulmonary exacerbation of cystic fibrosis

97.0%

also reported Hospitalization

54.0%

are women

Most common medical consequences

Hospitalization
97.0%
Severe reaction
2.5%
Death
0.2%
Life-threatening condition
0.2%

Have you experienced any negative side effects from this medication?

Orkambi: general information

Most common side effects (128)

Most commonly affected ages

0 - 9 years
19.9%
10 - 19 years
37.0%
20 - 29 years
23.4%
30 - 39 years
14.1%
40 - 49 years
5.1%
50 - 59 years
0.5%